KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue: 2009-2024

Historic Current Deferred Revenue for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $55.5 million.

  • Alnylam Pharmaceuticals' Current Deferred Revenue fell 96.42% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 96.42%. This contributed to the annual value of $55.5 million for FY2024, which is 80.92% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Current Deferred Revenue of $55.5 million as of FY2024, which was down 80.92% from $290.8 million recorded in FY2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Current Deferred Revenue peaked at $290.8 million during FY2023, and registered a low of $55.5 million during FY2024.
  • In the last 3 years, Alnylam Pharmaceuticals' Current Deferred Revenue had a median value of $235.5 million in 2022 and averaged $193.9 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Current Deferred Revenue soared by 57.56% in 2022 and then slumped by 80.92% in 2024.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Current Deferred Revenue stood at $127.2 million in 2020, then grew by 17.51% to $149.5 million in 2021, then spiked by 57.56% to $235.5 million in 2022, then rose by 23.45% to $290.8 million in 2023, then tumbled by 80.92% to $55.5 million in 2024.